TY - JOUR
T1 - Refractoriness and Conduction Interaction during Modulation of Non-Ischemic Ventricular Fibrillation by Flecainide
AU - Amitzur, Giora
AU - Shenkar, Nitza
AU - Mueller, Matthias
AU - Kraft, Patricia
AU - Novikov, Ilia
AU - Eldar, Michael
AU - Leor, Jonathan
AU - Raichlin, Eugenia
AU - Schoels, Wolfgang
N1 - Funding Information:
This study was supported by a grant from the Ministry of Science. Project No. DISMED0091/GR01368.
PY - 2003
Y1 - 2003
N2 - Purpose: To study refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation (VF) by flecainide. Methods: Isolated feline and rabbit hearts were used. (a) In the feline hearts (n = 8), electrophysiological parameters were measured before and after flecainide administration (0.6, 1.2 × 10-6 M). During pacing the parameters were: epicardial conduction time, refractoriness and 1:1 pacing/response capture. During 8 min of electrically-induced tachyarrhythmias they included heart rate and normalized entropy reflecting the degree of organization. (b) In rabbit hearts (n = 4), three-dimensional mapping was performed before and after flecainide administration (2 × 10-6 M). To follow changes in organization, local RR-intervals and differences in activation time between adjacent epicardial electrodes were measured immediately and 80 sec after VF induction. Results: In feline hearts with flecainide, fibrillation was more difficult to induce, more frequently terminated spontaneously and was slower and more organized; conduction time was markedly lengthened, and refractoriness less than 1:1 capture, was moderately prolonged. An inverse correlation was observed between arrhythmia properties, rate and organization, and changes in refractoriness and conduction time. In rabbit, the number of wave fronts was reduced, RR-intervals were prolonged but at the same time activation time differences between adjacent electrodes were smaller following flecainide administration. Conclusions: It is suggested that flecainide modulation of VF properties is associated with conduction suppression and refractoriness prolongation, which act in a synergistic, additive way.
AB - Purpose: To study refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation (VF) by flecainide. Methods: Isolated feline and rabbit hearts were used. (a) In the feline hearts (n = 8), electrophysiological parameters were measured before and after flecainide administration (0.6, 1.2 × 10-6 M). During pacing the parameters were: epicardial conduction time, refractoriness and 1:1 pacing/response capture. During 8 min of electrically-induced tachyarrhythmias they included heart rate and normalized entropy reflecting the degree of organization. (b) In rabbit hearts (n = 4), three-dimensional mapping was performed before and after flecainide administration (2 × 10-6 M). To follow changes in organization, local RR-intervals and differences in activation time between adjacent epicardial electrodes were measured immediately and 80 sec after VF induction. Results: In feline hearts with flecainide, fibrillation was more difficult to induce, more frequently terminated spontaneously and was slower and more organized; conduction time was markedly lengthened, and refractoriness less than 1:1 capture, was moderately prolonged. An inverse correlation was observed between arrhythmia properties, rate and organization, and changes in refractoriness and conduction time. In rabbit, the number of wave fronts was reduced, RR-intervals were prolonged but at the same time activation time differences between adjacent electrodes were smaller following flecainide administration. Conclusions: It is suggested that flecainide modulation of VF properties is associated with conduction suppression and refractoriness prolongation, which act in a synergistic, additive way.
KW - Conduction time
KW - Effective refractory period
KW - Flecainide
KW - Isolated heart
KW - Three-dimensional mapping
KW - Ventricular fibrillation
UR - http://www.scopus.com/inward/record.url?scp=0242637210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242637210&partnerID=8YFLogxK
U2 - 10.1023/A:1026124224369
DO - 10.1023/A:1026124224369
M3 - Article
C2 - 14574082
AN - SCOPUS:0242637210
SN - 0920-3206
VL - 17
SP - 237
EP - 247
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 3
ER -